Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

Kyle Rosenke, Frederick Hansen, Benjamin Schwarz, Friederike Feldmann, Elaine Haddock, Rebecca Rosenke, Kent Barbian, Kimberly Meade-White, Atsushi Okumura, Shanna Leventhal, David W. Hawman, Emily Ricotta, Catharine M. Bosio, Craig Martens, Greg Saturday, Heinz Feldmann () and Michael A. Jarvis ()
Additional contact information
Kyle Rosenke: National Institutes of Health
Frederick Hansen: National Institutes of Health
Benjamin Schwarz: National Institutes of Health
Friederike Feldmann: National Institutes of Health
Elaine Haddock: National Institutes of Health
Rebecca Rosenke: National Institutes of Health
Kent Barbian: National Institutes of Health
Kimberly Meade-White: National Institutes of Health
Atsushi Okumura: National Institutes of Health
Shanna Leventhal: National Institutes of Health
David W. Hawman: National Institutes of Health
Emily Ricotta: National Institutes of Health
Catharine M. Bosio: National Institutes of Health
Craig Martens: National Institutes of Health
Greg Saturday: National Institutes of Health
Heinz Feldmann: National Institutes of Health
Michael A. Jarvis: National Institutes of Health

Nature Communications, 2021, vol. 12, issue 1, 1-8

Abstract: Abstract The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-22580-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22580-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-22580-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().